Literature DB >> 6449507

Mucin synthesis. I. Detection in canine submaxillary glands of an N-acetylglucosaminyltransferase which acts on mucin substrates.

D Williams, H Schachter.   

Abstract

Canine submaxillary gland microsomes have been shown to catalyze the following reaction: UDP-GlcNAc + Gal beta 1-3GalNAc-X leads to Gal beta 1-3(GlcNAc)GalNAc-X + UDP where X is porcine or ovine submaxillary mucin polypeptide or a low molecular weight substituent. This activity was shown by mixed substrate experiments to be different from two other previously described glycoprotein N-acetylglucosaminyltransferases acting on N-glycosyl oligosaccharides and is the first N-acetylglucosaminyltransferase shown to act on mucin substrates. The transferase-catalyzed reaction proceeds at 70 to 80% of the optimum rate in the absence of added divalent cation or in the presence of 10 mM EDTA. The enzyme appeared to be unstable at 37 degrees C, but the reaction rate remained constant for at least 2 h at 25 degrees C. The enzyme showed a pH optimum of 7.0 and was stimulated 4-fold by 0.125% Triton X-100. Methylation analysis of product formed either with mucin acceptor or Gal beta 1-3GalNAc-alpha-O-benzyl indicated GlcNAc transfer to either carbon 4 or carbon 6 of the GalNAc residue of the acceptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6449507

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells.

Authors:  D Toki; M Sarkar; B Yip; F Reck; D Joziasse; M Fukuda; H Schachter; I Brockhausen
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy.

Authors:  B M Ben-Mahmud; W H Chan; R M Abdulahad; A Datti; A Orlacchio; E M Kohner; R Chibber
Journal:  Diabetologia       Date:  2006-07-11       Impact factor: 10.122

Review 3.  The joys of HexNAc. The synthesis and function of N- and O-glycan branches.

Authors:  H Schachter
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

4.  Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase.

Authors:  W Kuhns; V Rutz; H Paulsen; K L Matta; M A Baker; M Barner; M Granovsky; I Brockhausen
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

5.  Mucin biosynthesis. Properties of a bovine tracheal mucin beta-6-N-acetylglucosaminyltransferase.

Authors:  P W Cheng; W E Wingert; M R Little; R Wei
Journal:  Biochem J       Date:  1985-04-15       Impact factor: 3.857

6.  Control of core 2 beta1,6 N-acetylglucosaminyltransferase-I transcription by Sp1 in lymphocytes and epithelial cells.

Authors:  V Rebecca Falkenberg; Nevis Fregien
Journal:  Glycoconj J       Date:  2007-05-26       Impact factor: 2.916

7.  Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue.

Authors:  Y Nishio; C E Warren; J A Buczek-Thomas; J Rulfs; D Koya; L P Aiello; E P Feener; T B Miller; J W Dennis; G L King
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

8.  UDP-GlcNAc: Gal beta 3GalNAc-mucin: (GlcNAc----GalNAc) beta 6-N-acetylglucosaminyltransferase and UDP-GlcNAc: Gal beta 3(GlcNAc beta 6) GalNAc-mucin (GlcNAc----Gal)beta 3-N-acetylglucosaminyltransferase from swine trachea epithelium.

Authors:  S Sangadala; S Sivakami; J Mendicino
Journal:  Mol Cell Biochem       Date:  1991-03-13       Impact factor: 3.396

9.  C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells.

Authors:  Catherine A St Hill; Dahabo Baharo-Hassan; Mariya Farooqui
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.